Adaptimmune Therapeutics Q4 2022 Earnings Report $0.60 +0.00 (+0.82%) (As of 12/20/2024 05:51 PM ET) Earnings HistoryForecast Adaptimmune Therapeutics EPS ResultsActual EPS-$0.18Consensus EPS -$0.25Beat/MissBeat by +$0.07One Year Ago EPSN/AAdaptimmune Therapeutics Revenue ResultsActual Revenue$11.03 millionExpected Revenue$7.50 millionBeat/MissBeat by +$3.53 millionYoY Revenue GrowthN/AAdaptimmune Therapeutics Announcement DetailsQuarterQ4 2022Date3/6/2023TimeN/AConference Call ResourcesPress ReleaseADAP Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Adaptimmune Therapeutics Earnings HeadlinesAdaptimmune Therapeutics Announces Key Leadership ChangesDecember 19 at 3:12 PM | markets.businessinsider.comAdaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlookDecember 19 at 12:09 AM | uk.investing.comThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… December 22, 2024 | Crypto 101 Media (Ad)Adaptimmune Therapeutics (NASDAQ:ADAP) vs. Scinai Immunotherapeutics (NASDAQ:SCNI) Head-To-Head ComparisonDecember 18, 2024 | americanbankingnews.comEuropean Equities Traded in the US as American Depositary Rise in Thursday TradingDecember 5, 2024 | msn.comAdaptimmune Therapeutics: Strategic Restructuring and Promising Developments Drive ‘Buy’ RatingNovember 27, 2024 | markets.businessinsider.comSee More Adaptimmune Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptimmune Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptimmune Therapeutics and other key companies, straight to your email. Email Address About Adaptimmune TherapeuticsAdaptimmune Therapeutics (NASDAQ:ADAP), a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.View Adaptimmune Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
